The Venture Codex

Participated · Series C · Jun 2022

Diabeloop develops DBLG1, a closed-loop diabetes management system that integrates a continuous glucose sensor, an insulin pump and AI algorithms to automate insulin delivery for people with type 1 and highly unstable type 1 diabetes. The system’s algorithms analyze real-time glucose data and deliver personalized insulin doses based on patient parameters and entered information. DBLG1 completed clinical trials in 2017 and received CE marking in 2018. The solution is in use by more than 10,000 patients and has been deployed in France, Germany, Italy, Spain, Switzerland and the Netherlands. With a new €15 million funding round, the company intends to accelerate revenue growth of its closed-loop system and prepare the launch of DBLG2, an algorithm integrated into a smartphone app for Android and iOS. The company was founded in 2015 by Guillaume Charpentier and Erik Huneker and has appointed François Miceli as President and CEO. Diabeloop builds machine-learning software and CE-marked closed-loop systems (DBLG1 and DBL-hu) that connect continuous glucose monitors and insulin pumps to automate insulin delivery in real time. Its algorithms personalize therapy, reducing patient decision burden and aiming to improve clinical outcomes and quality of life. The company has commercially launched two products in Europe and was rapidly approaching 10,000 equipped patients one year after launch. Diabeloop also offers a CE-marked data-visualization telemedicine platform for clinicians and is adapting its core algorithm to the connected-pen market and developing smart-watch devices. Founded in 2015 and operating from Paris, the company employs over 160 people. The business plans to use new funding to accelerate commercial roll-out, international expansion and continued product development. Diabeloop is a Grenoble-based medical-technology spin-off founded in 2015 that develops the DBLG1, a hybrid closed-loop system for autonomous type 1 diabetes management. DBLG1 connects a continuous glucose monitor, an insulin patch pump and a locked-down handset that hosts a personalized, self-learning decision algorithm. The system uses layered safety mechanisms and machine-learning expert layers; Diabeloop owns related patents, some jointly with research partner CEA, and co-develops with CEA-Leti and CERITD. A randomized 68-person home trial published in The Lancet Digital Health showed significant improvement in glycemic control and reduced hypoglycemic risk; the study ran in 12 hospitals across France. Pediatric (ages 6–12) and highly unstable diabetes trials are ongoing, and the company plans a larger study for an FDA submission while pursuing reimbursement in France, discussions in Germany, and mid-term expansion across Europe. Diabeloop has also stated it will continue R&D to address other diabetes types and to further reduce the daily mental load of the disease.